HONG KONG, SHANGHAI and FLORHAM PARK, N.J., May 17, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that topline and subgroup results from the ESLIM-01 Phase III study of sovleplenib, as well as new and updated data related to novel investigational hematological malignancy therapies HMPL-306, HMPL-760 and tazemetostat, will be presented at the upcoming European Hematology Association (“EHA”) Hybrid Congress, taking place on June 13-16, 2024 in Madrid, ...

— Almost half a million people diagnosed each year across the globe — — Collaboration based on synergistic potential of inhibiting angiogenesis and tumor-associated macrophages with HUTCHMED's surufatinib and anti-PD-1 activity with Hengrui's camrelizumab, promoting the immune response against tumor cells — HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., May 14, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) today announces the initiation of a Phase II/III tr ...

HONG KONG, SHANGHAI, China and FLORHAM PARK, N.J., May 08, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED" or the "Company") (Nasdaq/AIM: ​HCM, HKEX:​ 13) today announces that Dr Renu Bhatia is appointed as an Independent Non-executive Director and a member of Technical Committee of the Company with effect from May 13, 2024. Dr Bhatia, a licensed physician, has over 25 years of experience in the healthcare, finance and fintech, and regulatory sectors. She is an experienced board director and ...

Investors might want to bet on HUTCHMED (HCM) , as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.The power of a chang ...

Shares of HUTCHMED (HCM) have gained 12.8% over the past four weeks to close the last trading session at $18.91, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $26.12 indicates a potential upside of 38.1%.The average comprises five short-term price targets ranging from a low of $17 to a high of $45, with a standard deviation of $11.60. While the lowest estimate indicates a decl ...

— If approved in the European Union, fruquintinib will be the first novel targeted therapy for metastatic colorectal cancer regardless of biomarker status in over a decade — — Positive opinion based on results from FRESCO-2 Phase III clinical trial — HONG KONG, SHANGHAI, China and FLORHAM PARK, N.J., April 26, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:​HCM; HKEX:​13) today announces that its partner Takeda (TSE:​4502/​NYSE:​TAK) received notification that the Committee for M ...

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., April 05, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the upcoming American Association of Cancer Research ("AACR") Annual Meeting 2024, taking place on April 5-10, 2024 in San Diego, California. Initial preclinical data will be presented for HMPL-506, a novel, highly potent and differentiate ...

ROCKVILLE, Md. and SUZHOU, China, April 2, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, and HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) today jointly announce that the New Drug Application ("NDA") for the combination of sintilimab and fruquin ...

Regulatory and Clinical Developments - The New Drug Application (NDA) for the combination of fruquintinib and sintilimab for advanced endometrial cancer has been accepted and granted priority review by the China National Medical Products Administration (NMPA) [1] - This is the first regulatory filing for fruquintinib in combination with an immune checkpoint inhibitor [3] - The NMPA granted Breakthrough Therapy designation to the combination in July 2023, recognizing its potential to address a serious condition with no effective treatment options [3] - The NDA is supported by data from the FRUSICA-1 study, a Phase II trial investigating the combination in endometrial cancer patients who failed prior systemic therapy [2] Endometrial Cancer Overview - Endometrial cancer is a common gynecological malignancy, with an estimated 417,000 global cases and 97,000 deaths in 2020 [4] - In China, approximately 82,000 people were diagnosed with endometrial cancer, resulting in 17,000 deaths in 2020 [4] - Recurrent and metastatic endometrial cancer remains an area of high unmet need with limited treatment options [4] Fruquintinib Profile - Fruquintinib is a selective oral inhibitor of VEGFR-1, -2, and -3, designed to inhibit tumor angiogenesis with enhanced selectivity and manageable safety [5] - It is approved in China for metastatic colorectal cancer and included in the National Reimbursement Drug List (NRDL) since January 2020 [6][7] - In the US, fruquintinib (marketed as FRUZAQLA™) received approval in November 2023 for metastatic colorectal cancer, supported by Phase III trials FRESCO and FRESCO-2 [8] Sintilimab Profile - Sintilimab, marketed as TYVYT® in China, is a PD-1 monoclonal antibody co-developed by Innovent and Eli Lilly [9] - It is approved in China for seven indications, including non-small cell lung cancer, hepatocellular carcinoma, and esophageal squamous cell carcinoma [9] - The combination of sintilimab and fruquintinib for advanced endometrial cancer has been granted priority review by the NMPA [10] Company Overview - HUTCHMED is a biopharmaceutical company focused on developing targeted therapies and immunotherapies for cancer and immunological diseases, with approximately 5,000 employees globally [11] - Innovent is a leading biopharmaceutical company with a mission to provide affordable biologics, having launched 10 products and with multiple assets in clinical development [12] Clinical Trial Data - The FRUSICA-1 study evaluated fruquintinib in combination with sintilimab in endometrial cancer patients, with primary and secondary endpoints including ORR, DCR, DoR, PFS, and OS [2] - Data from FRUSICA-1 will be presented at an upcoming medical conference [2]

— Oral presentation at the European Lung Cancer Congress 2024 of Phase IIIb data demonstrating median PFS of 13.7 months and median OS not reached in treatment-naïve patients — — If approved, would confirm 2021 conditional approval and expand indication to more patients — HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., March 27, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:​HCM; HKEX:​13) today announces that the supplemental New Drug Application ("sNDA") for savolitinib, ...